Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MVT 5873

Next Previous
Drug Profile

MVT 5873

Alternative Names: 5B1-(sLeA)-therapeutic; Anti-CA19.9 antibody; anti-sialyl Lewisa antibody; BNT-321; HuMab MVT-5873; HuMab-5B1; HuMab-5B1 antibody; MVT-5873

Latest Information Update: 13 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MabVax Therapeutics
  • Developer MabVax Therapeutics; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Sarah Cannon Research Institute
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cholangiocarcinoma; Colorectal cancer; Pancreatic cancer
  • No development reported Cancer; Non-small cell lung cancer; Small cell lung cancer

Most Recent Events

  • 18 Sep 2024 BioNTech terminates a phase I/II trial in Pancreatic cancer (Adjuvant therapy) in USA (IV) due to sponsor decision(NCT06069778)
  • 18 Jan 2024 Interim adverse events, efficacy, pharmacokinetics and pharmacodynamics data from a phase-I trial in Pancreatic cancer presented at the Gastrointestinal Cancers Symposium (ASCO-GCS-2024)
  • 28 Nov 2023 No recent reports of development identified for phase-I development in Pancreatic-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top